Literature DB >> 27625368

Prognostic impact of late gadolinium enhancement in the risk stratification of heart transplant patients.

Patrizia Pedrotti1, Claudia Vittori1,2, Rita Facchetti3, Stefano Pedretti4, Santo Dellegrottaglie1, Angela Milazzo1, Maria Frigerio2, Manlio Cipriani2, Cristina Giannattasio3,5, Alberto Roghi1, Ornella Rimoldi6,7.   

Abstract

AIMS: The aim of the present study was to assess the association of the presence and amount of late gadolinium enhancement (LGE) at cardiac magnetic resonance (CMR) with cardiovascular adverse events in patients with orthotopic heart transplantation (HTx). METHODS AND
RESULTS: We enrolled 48 patients (mean age, 54.7 ± 14.6 years; 37 men) at various stages after HTx. All patients underwent standard CMR at 1.5 T, to characterize both cardiac anatomy and LGE. Late gadolinium enhancement was detected in 26 patients (54%). All-cause and cardiovascular mortalities, and a composite of major adverse cardiovascular events (MACE) recurrence were evaluated during the follow-up period for a median of 5.16 years. Ten patients (21%) died and 26 (54%) were readmitted because of MACE. Multivariate Cox analysis identified as independent predictors of MACE a diagnosis of cardiac allograft vasculopathy (CAV) (HR 3.63; 1.5-8.7 95% CI; P = 0.0039), left ventricular end systolic volume index (HR 1.04; 95% CI 1.01-1.079; P = 0.008), LGE mass (HR 1.04; 1.01-1.06 95% CI; P = 0.0007), LGE % of left ventricular mass (HR 1.083; 1.03-1.13 95% CI; P = 0.0002). Independent predictors of all-cause death were CAV (HR 6.33; 95% CI 1.33-30.03; P = 0.0201), LGE mass (HR 1.04; 1.01-1.07 95% CI; P = 0.005), LGE % of left ventricular mass (HR 1.075; 1.02-1.13 95% CI; P = 0.007). Patients with CAV had a risk of MACE by 5 years of 67% (95% CI 0.309-0.851%); the addition of 7.9 LGE % to the risk model increased the predicted risk to 88% (95% CI 0.572-0.967%).
CONCLUSIONS: The current study demonstrated that the presence of CAV and the total amount of LGE have a significant independent association with MACE and mortality in HTx patients. Published on behalf of the European Society of Cardiology. All rights reserved.
© The Author 2016. For permissions please email: journals.permissions@oup.com.

Entities:  

Keywords:  cardiovascular magnetic resonance; coronary allograft vasculopathy; heart transplant; late gadolinium enhancement

Mesh:

Substances:

Year:  2016        PMID: 27625368     DOI: 10.1093/ehjci/jew186

Source DB:  PubMed          Journal:  Eur Heart J Cardiovasc Imaging        ISSN: 2047-2404            Impact factor:   6.875


  6 in total

1.  Myocardial Fibrosis and Prognosis in Heart Transplant Recipients.

Authors:  Andrew Hughes; Osama Okasha; Afshin Farzaneh-Far; Felipe Kazmirczak; Prabhjot S Nijjar; Pratik Velangi; Mehmet Akçakaya; Cindy M Martin; Chetan Shenoy
Journal:  Circ Cardiovasc Imaging       Date:  2019-10-15       Impact factor: 7.792

2.  Natural History of Myocardial Late Gadolinium Enhancement Predicts Adverse Clinical Events in Heart Transplant Recipients.

Authors:  Kongkiat Chaikriangkrai; Muhannad Aboud Abbasi; Roberto Sarnari; Daniel Lee; Allen S Anderson; Kambiz Ghafourian; Sadiya S Khan; Esther E Vorovich; Jonathan D Rich; Jane E Wilcox; Julie A Blaisdell; Clyde W Yancy; James Carr; Michael Markl
Journal:  JACC Cardiovasc Imaging       Date:  2019-07-17

Review 3.  Multi-modal imaging of the pediatric heart transplant recipient.

Authors:  Jonathan H Soslow; Margaret M Samyn
Journal:  Transl Pediatr       Date:  2019-10

4.  Multi-parametric cardiovascular magnetic resonance with regadenoson stress perfusion is safe following pediatric heart transplantation and identifies history of rejection and cardiac allograft vasculopathy.

Authors:  Nazia Husain; Kae Watanabe; Haben Berhane; Aditi Gupta; Michael Markl; Cynthia K Rigsby; Joshua D Robinson
Journal:  J Cardiovasc Magn Reson       Date:  2021-11-22       Impact factor: 5.364

5.  Association Between 2D- and 3D-Speckle-Tracking Longitudinal Strain and Cardiovascular Magnetic Resonance Evidence of Diffuse Myocardial Fibrosis in Heart Transplant Recipients.

Authors:  Wei Sun; Xuehua Shen; Jing Wang; Shuangshuang Zhu; Yanting Zhang; Chun Wu; Yuji Xie; Yun Yang; Nianguo Dong; Guohua Wang; Yuman Li; Qing Lv; Bo Liang; Li Zhang; Mingxing Xie
Journal:  Front Cardiovasc Med       Date:  2021-11-30

6.  Prognostic Value of Myocardial Extracellular Volume Fraction and T2-mapping in Heart Transplant Patients.

Authors:  Kongkiat Chaikriangkrai; Muhannad Aboud Abbasi; Roberto Sarnari; Ryan Dolan; Daniel Lee; Allen S Anderson; Kambiz Ghafourian; Sadiya S Khan; Esther E Vorovich; Jonathan D Rich; Jane E Wilcox; Julie A Blaisdell; Clyde W Yancy; James Carr; Michael Markl
Journal:  JACC Cardiovasc Imaging       Date:  2020-03-18
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.